Abattis Bioceuticals Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ATTBF research report →
Price Chart
About the company
Abattis Bioceuticals Corp. operates as a life sciences and biotechnology company in Canada. The company develops and licenses natural health products, medicines, extractions, and ingredients for the biological, nutraceutical, bioceutical, and cosmetic markets.
- CEO
- Robert G. Goodall
- IPO
- 2014
- Employees
- 48
- HQ
- Vancouver, BC, CA
Get TickerSpark's AI analysis on ATTBF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $14.33K
- P/E
- -0.01
- PEG
- -0.00
- P/S
- 0.06
- P/B
- 0.00
- EV/EBITDA
- 0.15
- Div Yield
- 0.00%
- Gross Margin
- 67.62%
- Op Margin
- -1108.73%
- Net Margin
- -852.40%
- ROE
- -26.96%
- ROIC
- -25.05%
Latest fiscal year · YoY change
- Revenue
- $356.88K+4163.2%
- Gross Profit
- $241.34K+3626.0%
- Op Income
- $-3,956,802
- Net Income
- $-3,042,005+96.1%
- EPS
- $-0.01+97.3%
- OCF Growth
- +213.7%
- FCF Growth
- +151.1%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 1.77
- RSI (14)
- 46
- Avg Volume
- 21.66K
No earnings-call transcripts are available for ATTBF yet.
- Free Float
- 99.6%
- Shares Outstanding
- 477.80M
- Float Shares
- 475.90M
Our ATTBF coverage
Recent articles, reports, and earnings notes.
No research on ATTBF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ATTBF report →